Replicant–STAV Lipid Nanoparticles for Tumor Immunogenicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Tumor cells are notoriously non-immunogenic due to their ability to mimic normal cells, evading immune activation, and there are no effective treatment options for HTLV-1 associated diseases like ATLL and HAM/TSP.

Innovation Solution

Development of DNase-resistant nucleic acid-based STING-dependent adjuvants (STAVs) combined with RNA to render tumor cells immunogenic, stimulating antigen-presenting cells (APCs) and generating a humoral immune response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If tumor cells are used as they are, then they can be easily administered, but they remain non-immunogenic and fail to stimulate immune response

Engineering Contradiction:

ImproveimmunogenicityVSAvoidcomposition complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines tumor cells with STING-dependent adjuvants (STAVs) and RNA molecules into a composite immunogenic composition. This merging transforms non-immunogenic tumor cells into immunogenic vaccine compositions that can stimulate potent cytotoxic T-cell responses while maintaining the simplicity of cell-based administration

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite material system consisting of tumor cells modified with STAVs and RNA. This composite approach integrates multiple functional components (tumor cell structure, STING pathway activation, antigen expression) into a single therapeutic agent that achieves both immunogenicity and ease of administration

Inventive Principle:

Principle #40Composite materials

2Reliability

If conventional chemotherapy is used for ATLL treatment, then it can be administered readily, but it provides no effective treatment options and carries dismal prognosis

Engineering Contradiction:

Improvetreatment efficacyVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent uses STING-dependent adjuvants (STAVs) as intermediary molecules that bridge the gap between conventional chemotherapy approaches and effective cancer treatment. These STAVs act as mediators that activate the STING pathway in antigen-presenting cells, triggering potent immune responses against tumor cells without requiring complex multi-agent chemotherapy regimens

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention replaces the mechanical/cellular approach of conventional chemotherapy with a molecular signaling approach. Instead of using cytotoxic drugs that directly kill cells, the patent uses STAVs and RNA to trigger intracellular STING signaling pathways, substituting direct cellular destruction with molecular-level immune system activation

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If STAVs and RNA are combined with tumor cells to enhance immunogenicity, then potent cytotoxic T-cell activity is generated, but the composition becomes more complex

Engineering Contradiction:

Improveimmune response potencyVSAvoidcomposition structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent creates a universal composition platform where tumor cells serve multiple functions: providing structural integrity, delivering STAVs to antigen-presenting cells, and expressing tumor antigens through co-administered RNA. This multi-functionality reduces the need for separate components while achieving potent immune responses

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

STAVs and RNA combination effectively stimulates APCs, generating potent cytotoxic T-cell activity against cancer cells and infectious agents, offering a therapeutic approach for diseases like ATLL, AML, and ALL.

Implementation Method 1

STimulator of Interferon Genes (STING) is activated by cyclic dinucleotides (CDN's) such as cyclic di-GMP and cyclic-di-AMP secreted by intracellular bacteria following infection. Alternatively, STING can be activated by cyclic GMP-AMP (cGAMP) generated by a cellular cGAMP synthase cGAS (MB21D1) after association with aberrant cytosolic dsDNA species

Methodology Applied

Scientific EffectSTING signaling:

Data Source

PatentUS20250332233A1Replicant / STAV for disease treatment and methods of use

Publication Date: 2025.10.30 BARBER GLEN N

AI summary

Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) together with Replicants including mRNA adapted to express an antigen can be delivered to antigen presenting cells (APC's) using lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV/Replicant therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers the STAV/Replicant into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity together with humoral immune responses. The STAV/Replicant formulations can be introduced into solid tumors present in the subject. Alternatively, the STAV/Replicant can be introduced through direct inoculation, intramuscularly, or intravenously. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's.